EUCTR2008-006384-37-NL进行中（未招募）不适用
A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC).
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent
- •2. Patient ability to comply with protocol requirements (visits and assessment schedules).
- •3. Stage IIIB/IV histologically-confirmed NSCLC that is recurrent or refractory to at most 2 lines of therapy for metastatic disease. Therapy is limited to:
- •First line - platinum containing regimen - bevacizumab
- •Second line - Single-agent EGFR targeted therapies. Acceptable agents include either smallmolecule tyrosine kinase inhibitors (i.e. gefitinib or erlotinib) or monoclonal antibodies. Acceptable agents include either smallmolecule tyrosine kinase inhibitors (i.e. gefitinib or erlotinib) or monoclonal antibodies.
- •Other therapies are not allowed.
- •4. Patients must have a measurable disease by contrast enhanced CT and detectable by PET scanning. Screening tumor evaluation should be performed within 7 days before the first study drug administration. The Investigator/designee with assess the PET and CT scans to confirm patient eligibility.
- •5. Adult patients aged =18 yrs.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
- •7. Adequate liver function: Total bilirubin = 1.5 mg/dL, AST and ALT = 2.5x institutional ULN (or = 5 x ULN if liver metastases present); alkaline phosphatase = 2.5x ULN (or = 5 x ULN if liver or bones metastases present).
- •8. Adequate renal function: serum creatinine = 1.5 mg/dL or creatinine clearance estimate = 45 mL/min (according to Cockroft-Gault formula)
- •9. Adequate bone marrow function, defined by: ANC = 1.5 x 10 exp9/L, platelets = 100 x 10 exp9/L, and hemoglobin = 8.5 g/dL. Patients should not require chronic supportive growth factor administration or transfusions to meet treatment eligibility criteria (e.g., G-CSF for ANC eligibility).
- •10. Women of child-bearing potential and women less than 2 years after menopause must have a negative urine pregnancy test result within 72 hours prior to the start of study drug administration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Treatment with any investigational agent within 28 days of first receipt of study drug.
- •2. Prior chemotherapy or radiotherapy within 4 weeks (other than a short cycle of palliative radiotherapy for bone pain) of first receipt of study treatment.
- •3. Patients unable to swallow oral medications or with preexisting GI disorders that might interfere with proper absorption of the oral drug.
- •4. History of other malignancy, either primary or recurrent, within the past 2 years, except basal cell skin carcinoma or in situ cervical carcinoma.
- •5. History of active seizure disorder (e.g. event = 2 months prior to start of study).
- •6. Patients with a history of CNS metastases or leptomeningeal metastases, except for those who have clinically stable disease characterized by all the following:
- •surgical resection and/or radiotherapy completed = 2 months prior to first dosing.
- •no corticosteroid requirements for CNS disease for = 4 weeks prior to first dosing.
- •stable disease measured by CT or MRI within 4 weeks of first dosing.
- •stable neurologic exam (no new global or focal abnormalities) for at least 4 weeks prior to first dosing.
- •To confirm eligibility, a discussion between the Investigator and Sponsor is required for patients with CNS disease.
- •7. Serious cardiovascular illness including but not confined to symptomatic CHF, unstable angina pectoris, symptomatic cardiac arrhythmia or cardiac pacemaker requirement.
- •8. QTcF > 450 msec (males) and QTcF > 470 msec (females) at screening.
- •9. Other uncontrollable, concurrent illness including, but not limited to: significant hypoxia requiring chronic oxygen therapy; active or uncontrolled infection, altered mental status or psychiatric illness that would limit compliance with study requirements.
- •10. Pregnant women and women who are breast feeding.
- •11. Unwillingness or inability to use acceptable (e.g. barrier) method of contraception during study and up to 4 weeks post last dose of study medication for non-sterile men and women of child-bearing potential and women less than 2 years after menopause.
- •12. Patients receiving CYP3A4 substrates, or inhibitors within 7 days prior to receipt of study drug and CYP3A4 inducers within 14 days prior receipt of study drug.
- •13. Major surgery within 28 days of first receipt of study drug.
- •14. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that in the opinion of the Investigator, contraindicates the use of an investigational drug, or that may render the patient at excessively high risk for treatment complications.
研究者
相似试验
进行中（未招募）
不适用
A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a platinum-based non-taxane regimen - N/AEUCTR2004-000696-34-HUDaiichi Pharmaceutical Co., Ltd37
已完成
2 期
Phase IIa examination of the effect of oral dosing of NV-52 on surrogate markers of inflammatory bowel disease (IBD) in patients with stable disease but with a consistent abnormality in one or more surrogate marker.ACTRN12607000617460ovogen Research Pty Ltd10
招募中
2 期
Phase II study of prophylactic oral administration of diltiazem for atrial fibrillation after lung resectioatrial fibrillation after lung resectionJPRN-UMIN000001691Department of Surgical Oncology, Hokkaido University Graduate School of Medicine124
进行中（未招募）
不适用
A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinomaPatients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinomaMedDRA version: 14.1Level: LLTClassification code 10014745Term: Endometrial carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024396-12-ITOVARTIS FARMA140
进行中（未招募）
1 期
BKM120 as second-line therapy in advanced endometrial cancerEUCTR2010-022015-19-BEovartis Pharma Services AG161